2025-12-31 - Analysis Report
Okay, here's a comprehensive analysis of Eli Lilly and Co. (LLY) based on the provided data, broken down into sections:

**1) Return Comparison vs. S&P 500 (VOO)**

*   **Company Overview:** Eli Lilly and Co. is a major pharmaceutical company focused on developing and marketing innovative medicines.
*   **LLY Cumulative Return:** 308.74%
*   **VOO Cumulative Return:** 102.21%
*   **Divergence:** 204.8 (Relative Divergence: 84.5)

**Analysis:** LLY has significantly outperformed the S&P 500 over the tracked period.  The divergence in returns is substantial (204.8%), indicating a significantly stronger growth trajectory for LLY compared to the broader market. The relative divergence of 84.5 suggests the current divergence is high compared to its historical range.

**Alpha, Beta Analysis**

| Year       | CAGR    | MDD   | Alpha   | Beta  | Cap(B) |
|------------|---------|-------|---------|-------|--------|
| 2015-2017  | 11.0%   | 76.1% | -17.0%  | -0.0  | 75.7   |
| 2016-2018  | 39.0%   | 68.9% | 24.0%   | -0.0  | 103.7  |
| 2017-2019  | 41.0%   | 68.9% | 19.0%   | 0.4   | 117.8  |
| 2018-2020  | 34.0%   | 79.8% | 10.0%   | 0.4   | 151.4  |
| 2019-2021  | 53.0%   | 79.8% | 7.0%    | 0.5   | 247.6  |
| 2020-2022  | 64.0%   | 79.8% | 65.0%   | 0.4   | 328.0  |
| 2021-2023  | 125.0%  | 78.9% | 124.0%  | 0.2   | 522.6  |
| 2022-2024  | 134.0%  | 81.2% | 113.0%  | 0.2   | 692.1  |
| 2023-2025  | 200.0%  | 83.5% | 133.0%  | 0.2   | 968.0  |

**Analysis:**

*   **CAGR:**  Shows significant growth acceleration in recent periods, particularly from 2020-2025.
*   **MDD (Maximum Drawdown):**  High MDD values (above 68%) suggest significant price volatility and potential risk.
*   **Alpha:** The high and increasing Alpha values (especially from 2020 onward) indicate that LLY is generating returns above what would be expected based on its beta (market risk).  This suggests strong stock-specific performance, likely driven by company-specific factors.
*   **Beta:** Beta values generally around 0.4 to 0.5 indicate that LLY is less volatile than the market as a whole.
*   **Cap(B):**  The market capitalization of the company has increased significantly from 75.7B to 968.0B.

**2) Recent Stock Price Fluctuations**

*   **Current Price:** 1079.75
*   **Previous Close:** 1078.73
*   **Change:** 0.09
*   **5-day SMA:** 1076.97
*   **20-day SMA:** 1042.203
*   **60-day SMA:** 960.5238

**Analysis:**  The price is currently above all moving averages. The 5-day SMA is very close to the current price, while the 20-day and 60-day SMAs are significantly lower, suggesting a recent upward trend. The small positive change from the previous close (0.09) suggests a relatively stable price in the very short term.

**3) Market Risk Indicators and Expected Return**

*   **MRI:** 0.9 (High Investment Recommended)
*   **RSI:** 82.95 (Overbought)
*   **PPO:** -0.0633
*   **Hybrid Signal:** Buy 100% (Very Safe, MRI: 0.9)
*   **Recent Relative Divergence Change:** 1.3 (+), indicating short-term increase
*   **Expected Return:** 49.3%

**Analysis:**

*   The **MRI** suggests that the current market conditions are favorable for investment in LLY.
*   The **RSI** is in overbought territory, which could indicate a potential for a pullback or consolidation in the near term.
*   The **PPO** is slightly negative.
*   The **Hybrid Signal** indicates a strong buy recommendation, reinforcing the MRI signal.
*   The positive change in recent relative divergence suggests a short-term upward trend compared to the comparison stock (VOO).
*   The **expected return** of 49.3% is very high, implying significant potential upside if held long-term (2+ years).

**4) Recent News & Significant Events:**

*   **Weight-loss pill pricing and insider filings:** Indicates continued focus and potential impact on LLY's value due to obesity drugs.
*   **LLY as a Top Stock Split Candidate in 2026:** Suggests the company's stock price is anticipated to continue rising, making a split necessary for accessibility.
*   **Option Activity:** High options activity often precedes or follows significant price movements.
*   **Stocks to Watch:** Inclusion in "Stocks to Watch" lists indicates analyst and investor interest.
*   **J. L. Bainbridge & Co. Inc. increased position:**  Indicates institutional confidence in LLY.

**Analysis:** The news flow is generally positive, with a focus on potential growth drivers (weight loss drugs), future stock splits (signaling high price), and institutional interest. The options activity suggests heightened investor attention, and the stock split consideration would create more liquidity for individual investors.

**4-2) Analyst Opinions:**

*   **Consensus:** Buy (1.70)
*   **Target Price:** $1093.22 (Mean)

**Analysis:**  Analyst consensus is strongly bullish on LLY, with a mean target price slightly above the current price.

**5) Recent Earnings Analysis:**

| 날짜       | EPS   | 매출      |
|------------|-------|-----------|
| 2025-10-30 | 6.22  | 17.60 B$  |
| 2025-08-07 | 6.3   | 15.56 B$  |
| 2025-05-01 | 3.07  | 12.73 B$  |
| 2024-10-30 | 1.08  | 11.44 B$  |
| 2025-10-30 | 1.08  | 11.44 B$  |

**Analysis:** The earnings data shows a strong growth trend in both EPS (Earnings Per Share) and revenue over the recent quarters.  EPS has increased substantially, and revenue has followed suit.

**6) Financial Information:**

**Revenue and Profitability:**

| Quarter      | Revenue   | Profit Margin |
|--------------|-----------|---------------|
| 2025-09-30   | $17.60B   | 82.91%       |
| 2025-06-30   | $15.56B   | 84.27%       |
| 2025-03-31   | $12.73B   | 82.53%       |
| 2024-12-31   | $13.53B   | 82.24%       |
| 2024-09-30   | $11.44B   | 81.02%       |

**Capital and Profitability:**

| Quarter      | Equity    | ROE       |
|--------------|-----------|-----------|
| 2025-09-30   | $23.79B   | 23.46%    |
| 2025-06-30   | $18.27B   | 30.98%    |
| 2025-03-31   | $15.76B   | 17.50%    |
| 2024-12-31   | $14.19B   | 31.07%    |
| 2024-09-30   | $14.24B   | 6.81%     |

**Analysis:**

*   **Revenue and Profitability:** Revenue shows a consistent upward trend.  Profit margins are remarkably high and stable, indicating strong pricing power and efficient cost management.
*   **Capital and Profitability:**  Equity has increased significantly, reflecting growing retained earnings.  ROE (Return on Equity) is volatile but generally high, suggesting efficient utilization of shareholder equity to generate profits.

**7) Comprehensive Analysis (Summary):**

Eli Lilly (LLY) presents a compelling investment case based on the provided data.

*   **Outperformance:** LLY has significantly outperformed the S&P 500, demonstrating strong growth potential.
*   **Strong Fundamentals:**  The company exhibits robust revenue and earnings growth, along with exceptionally high profit margins.
*   **Positive Sentiment:** Analyst consensus is bullish, news flow is positive, and institutional investors are increasing their positions.
*   **Technical Indicators:** While the RSI suggests the stock may be overbought in the short term, other indicators like the MRI and Hybrid Signal support a buy recommendation. The moving averages confirm an overall upward trend.
*   **Growth Drivers:** The company's focus on innovative medicines, particularly in areas like obesity, is a key driver of future growth expectations.

**Conclusion:**  LLY appears to be a strong investment candidate, driven by solid fundamentals, positive market sentiment, and promising growth prospects. However, the high RSI suggests potential for short-term volatility. Investors should be aware of the potential for pullbacks and manage their risk accordingly.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.